

Company profile

Medios AG is one of the leading Specialty Pharma companies in Germany. As wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of patient-specific medications, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Specialty Pharma drugs are, in particular, individualised infusions for patients with rare or chronic diseases like cancer, HIV and hepatitis. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Management




Manfred Schneider, CEO
 • Pharmacist
 More than 20 years of pharmacy markets experience



Matthias Gärtner, CFO
 • IT Specialist
 More than 20 years of financial markets experience




Mi-Young Miehler, COO
 • Business Economist
 Business development specialist




Christoph Prußeit, CIO
 • Pharmacist
 Expert in the area of pharmaceutical production and safety


Group structure and segments



Consolidated sales in EUR million (IFRS, pro forma)



Consolidated EBT in EUR million (IFRS, pro forma)



* Compound Annual Growth Rate; ** 2017 Sales and EBT IFRS; before special charges from stock option program, non-cash effective

Contact

MEDIOS AG, Friedrichstr. 113a, 10117 Berlin, Telephone: +49 030 232 566 8-32, Fax: +49 030 232 566 8-01, ir@medios.ag, www.medios.ag

Key figures of Medios Group

*before special charges from stock option program; non-cash effective

in EUR million	2016 (IFRS, pro forma)	2017 (IFRS)	Change
Sales revenue	160.4	254.0	58.4%
Operating result (EBIT)	5.78	8.1*	40.1%
EBIT margin in %	3.60	3.20	-0.4 PP
Earnings before taxes (EBT)	5.77	8.0*	38.7%
EBT margin in %	3.60	3.20	-0.4 PP
Consolidated net income before minority interests	3.91	4.1	4.9%
Consolidated net income after minority interests	3.12	4.1	34.4%

Basic information


Share capital EUR 14,564,019
 No. of shares 14,564,019
 Share class No-par value bearer shares
 Share price EUR 15.45 (as of: November 16, 2018)
 Market capital. EUR 225 m
 WKN/ISIN A1MMCC/DE000A1MMCC8
 Trading places Regulated Market Frankfurt and Hamburg (General Standard)

Shareholder structure

M. Schneider (mediosmanagement GmbH) 56.0%
 direct 8,3%, addition 47,7%
CRANACH-PHARMA GmbH 3.4%
Freefloat 40.5%
 thereof:
 Claudia Neuhaus 3.5%, Marcel Jo Maschmeyer 3.0%

Share price

Status 16.11.2018



Investment highlights

- Uniquely positioned in the **growth segment** of specialty pharmaceuticals
- **First Mover** with clearly defined competitive advantages in the area of individualised medicine
- Ongoing profitable capital growth (**Proof of concept**)
- A **clear strategy** for further sales and earnings growth
- Management with many **years of industry and capital market experience**

Contact

MEDIOS AG, Friedrichstr. 113a, 10117 Berlin, Telephone: +49 030 232 566 8-32, Fax: +49 030 232 566 8-01, ir@medios.ag, www.medios.ag